Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RCHY1
REST API REST API
Homo sapiens
RCHY1 is differentially expressed in 305 experiments: 123 organism parts: liver, testis, ... (121 more);, 220 disease states: normal, glioblastoma, ... (218 more);, 84 cell types 450 cell lines 47 compound treatments and 79 other conditions.
Synonyms CHIMP, PRO1996, ARNIP, RNF199, ZNF363, DKFZp586C1620
Orthologs A4IFE2_BOVIN (Bos taurus)   RCHY1 (Gallus gallus)   rchy1 (Danio rerio)   Rchy1 (Rattus norvegicus)   ENSCING00000003118 (Ciona intestinalis)   Rchy1 (Mus musculus)   CG16947 (Drosophila melanogaster)   rchy1 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term ligase activity, protein binding, nuclear speck, protein autoubiquitination, cytoplasm, positive regulation of proteasomal ubiquitin-dependent protein catabolic process, protein ubiquitination, positive regulation of protein ubiquitination, metal ion binding, receptor binding, protein ubiquitination involved in ubiquitin-dependent protein catabolic process, nucleus, ubiquitin-protein ligase activity, electron carrier activity, ubiquitin ligase complex, protein homodimerization activity, zinc ion binding, p53 binding
InterPro Term Znf_CHY, Znf_RING, Znf_C3HC4_RING-type
UniProt Accession Q2KN33, Q96PM5, D6RAF6, Q96BL1, E7EMC8, E7ETW5
Search EB-eye ENSG00000163743
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (42 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
HL-60
2
E-MTAB-37, E-GEOD-24147
A549
2
E-GEOD-3202, E-GEOD-6013
BT-474
2
E-GEOD-3529, E-GEOD-5823
HCC1143
2
E-MTAB-37, E-MTAB-62
444 more value(s).


Cell type

studied in E-GEOD-3920, E-GEOD-13909, E-GEOD-20677, E-GEOD-13987, E-GEOD-21750, ... (40 experiments)

Factor Value U/D Experiments
CD34+
2
E-TABM-145, E-AFMX-5
stromal cell
2
E-GEOD-1460, E-GEOD-10797
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
CD71+ early erythroid
2
E-AFMX-5, E-TABM-145
mononuclear
2
E-GEOD-13987, E-GEOD-26672
78 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1577, E-MEXP-1121, E-GEOD-16363, E-MTAB-62, ... (58 experiments)

Factor Value U/D Experiments
glioblastoma
1
4
E-GEOD-4290, E-MTAB-37, E-GEOD-4412, E-GEOD-6014, E-MTAB-62 ... (5 experiments)
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
pancreatic carcinoma
2
E-MTAB-37, E-MEXP-1121
T-cell acute lymphoblastic leukemia
2
E-MTAB-37, E-GEOD-1577
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
chronic myelogenous leukemia
2
E-MTAB-62, E-MTAB-37
214 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-GEOD-697, ... (31 experiments)

Factor Value U/D Experiments
none
4
10
E-GEOD-5824, E-GEOD-2803, E-TABM-868, E-GEOD-412, E-MEXP-1958, ... (14 experiments)
placebo
2
E-MEXP-1327, E-MEXP-1335
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
valproic acid
1
E-GEOD-1615
sapphyrin PCI-2054
1
E-GEOD-6400
phorbol 12-myristate 13-acetate + ionomycin
1
E-GEOD-3720
41 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-19348, E-GEOD-22513, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-GEOD-4667, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-GEOD-22148, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, E-TABM-868, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-TABM-440, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-GEOD-3720, ... (43 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12254, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-26495, E-GEOD-1309, E-GEOD-21750, E-GEOD-5824, E-GEOD-5820 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-19743, E-GEOD-22541, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-4922

Tumor size
studied in E-GEOD-8167, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.451 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM